Sumiki's acid, a DE novo dietary compound generated from food processing, reprograms NK cells for cancer immunoprevention
Active Project Grant Awarded Last action
- Award ID
- K99CA303782
- Recipient
-
The University Of Chicago UEI ZUE9HKT2CLC9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $113,203
Award facts
- Assistance listing
- 93.398 Cancer Research Manpower
- Completion date 48% complete
- Originally
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Description
- Abstract
- Immunoprevention has emerged as a promising approach to reducing cancer risk, with most efforts in vaccines development, or repurposing of immune checkpoint inhibitors (ICIS). However, whether dietary small molecule substances as effective immunomodulators for cancer immunoprevention is largely unknown. Emerging evidence suggests a link between the DE novo substances generated from food processing and immunomodulation and a reduced risk of certain cancers. Considering the vital immunosurveillance roles of NK cell against tumorigenesis, we hypothesize that certain DE novo substances generated from food processing may act as bioactive compounds (named defpbioc) with immunomodulatory functions, exerting a direct and specific influence on NK cells and related immunity to inhibit tumorigenesis. We assembled a novel defpbioc library and systematically examined their direct effects on NK cell-dependent cytotoxicity against cancer cell. Sumiki's acid (SKA), generated from millard reaction during food processing by hearing, or microbiota biosynthesis, was identified as top candidate, which can significantly enhance the activation and cytotoxic functions of both primary human NK cells and mouse NK cells. The oral administration of SKA boosts NK- mediated anti-tumor immunity in various therapeutic mouse models, which encourages me to further determine its potential as a cancer-preventive agent in spontaneous gemm and carcinogen-induced colon cancer models (aim 1), and elucidate the underlying molecular mechanism (aim 2). In addition, I aim to perform medicinal chemistry studies for newly designed molecules with improved potency, and bioengineering of GUT-microbiota for SKA in situ production for more effective and sustain cancer-preventive effects (aim 3). The scientific knowledge and technical skills gained from these studies as well as my research training plan will help me develop a unique research direction and facilitate transition into independence. I will extend my independent research by focusing on the GUT-resident immunity, investigating how DE novo metabolites generated from microbiota-mediated nutrient processing (named micronutrimetabolites, mnms) regulate diverse GUT residential immune cells and related immunity response for colon cancer immunoprevention.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $113,203 |
Quick answers
Who received award K99CA303782?
K99CA303782 was awarded to The University Of Chicago by National Cancer Institute (National Institutes of Health) on August 1, 2025.
How much is award K99CA303782 worth?
$113,203 has been obligated on K99CA303782.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award